Opko Health Inc. (NASDAQ:OPK) has received a consensus recommendation of “Hold” from the ten ratings firms that are covering the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $15.64.
A number of brokerages recently issued reports on OPK. Standpoint Research reaffirmed a “buy” rating on shares of Opko Health in a report on Friday, December 30th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 price target (down from $20.00) on shares of Opko Health in a report on Tuesday, January 3rd. Laidlaw reaffirmed a “buy” rating and issued a $19.00 price target (down from $22.00) on shares of Opko Health in a report on Tuesday, January 3rd. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Finally, TheStreet downgraded Opko Health from a “c-” rating to a “d+” rating in a report on Wednesday, February 1st.
In other news, CEO Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock in a transaction on Friday, January 13th. The stock was bought at an average price of $9.15 per share, for a total transaction of $137,250.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $28,080,901.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Adam Logal sold 112,975 shares of the business’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $8.07, for a total value of $911,708.25. Following the completion of the sale, the insider now owns 234,996 shares of the company’s stock, valued at approximately $1,896,417.72. The disclosure for this sale can be found here. Insiders purchased 549,200 shares of company stock valued at $4,393,570 over the last ninety days. 40.74% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of OPK. Norges Bank purchased a new stake in shares of Opko Health during the fourth quarter worth $30,421,000. State Street Corp boosted its stake in shares of Opko Health by 3.0% in the fourth quarter. State Street Corp now owns 7,787,875 shares of the company’s stock worth $72,427,000 after buying an additional 226,132 shares in the last quarter. Whalerock Point Partners LLC purchased a new stake in shares of Opko Health during the third quarter worth $2,100,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Opko Health during the third quarter worth $622,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Opko Health during the fourth quarter worth $648,000. Institutional investors own 22.58% of the company’s stock.
Shares of Opko Health (NASDAQ:OPK) traded down 0.52% during midday trading on Monday, hitting $7.62. 3,044,692 shares of the stock were exchanged. The firm has a 50 day moving average of $7.93 and a 200-day moving average of $9.33. The company’s market cap is $4.25 billion. Opko Health has a one year low of $7.13 and a one year high of $12.15.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, March 1st. The company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04). Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The business earned $275.50 million during the quarter, compared to the consensus estimate of $310.82 million. The firm’s quarterly revenue was down .3% on a year-over-year basis. Equities analysts expect that Opko Health will post ($0.10) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://sleekmoney.com/brokerages-set-opko-health-inc-opk-price-target-at-15-64/1739714.html.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/brokerages-set-opko-health-inc-opk-price-target-at-15-64/1739714.html
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.